Abstract:Background: Yellow fever is a mosquito-borne viral hemorrhagic disease transmitted by several species of virus-infected mosquitoes endemic to tropical regions of Central and South America and Africa. Earlier in the twentieth century, mass vaccination integrated with mosquito control was implemented to eradicate the yellow fever virus. However, regular outbreaks occur in these regions which pose a threat to travelers and residents of Africa and South America. There is no specific antiviral therapy, but there can be an effective peptide-based vaccine candidate to combat infection caused by the virus. Therefore, the study aims to design a multi-epitope-based subunit vaccine (MESV) construct against the yellow fever virus to reduce the time and cost using reverse vaccinology (RV) approach. Methods: Yellow fever virus contains 10,233 nucleotides that encode for 10 proteins (C, prM, E, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) including 3 structural and 7 non-structural proteins. Structural proteins-precursor membrane protein (prM) and envelope protein (E)-were taken as a target for B cell and T cell epitope screening. Further, various immunoinformatics approaches were employed to FASTA sequences of structural proteins to retrieve B cell and T cell epitopes. MESV was constructed from these epitopes based on allergenicity, antigenicity and immunogenicity, toxicity, conservancy, and population coverage followed by structure prediction. The efficacy of the MESV construct to bind with human TLR-3, TLR-4, and TLR-8 were evaluated using molecular docking and simulation studies. Finally, in-silico cloning of vaccine construct was performed withpBR322 Escherichia coli expression system using codon optimization. Results: Predicted epitopes evaluated and selected for MESV construction were found stable, non-allergenic, highly antigenic, and global population coverage of 68.03% according to in-silico analysis. However, this can be further tested in in-vitro and in-vivo investigations. Epitopes were sequentially merged to construct a MESV consisting of 393 amino acids using adjuvant and linkers. Molecular docking and simulation studies revealed stable and high-affinity interactions. Furthermore, in-silico immune response graphs showed effective immune response generation. Finally, higher CAI value ensured high gene expression of vaccine in the host cell. Conclusion: The designed MESV construct in the present in-silico study can be effective in generating an immune response against the yellow fever virus. Therefore, to prevent yellow fever, it can be an effective vaccine candidate. However, further downstream, in-vitro study is required.

Development and Characterization of Monoclonal Antibodies to Yellow Fever Virus and Application in Antigen Detection and IgM Capture ELISA

Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope.

Synthesis of Truncated DNA Aptamer and Its Application to an Electrochemical Biosensor Consisting of an Aptamer and a MXene Heterolayer for Yellow Fever Virus

First DFT-supported point of care and novel electrochemical biosensing: Determination of yellow fever NS1 antibody in human plasma

Seroprevalence and molecular analysis of yellow fever virus in mosquitoes at Namanga and Mutukula borders in Tanzania

Preparation and Characterization of Monoclonal Antibody Against M Protein of Dengue Virus Serotype 2

Preparation of monoclonal antibodies against Yamagata-lineage influenza B virus hemagglutinin protein and establishment of a dual antibody sandwich ELISA detection method

Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Development and validation of RT-LAMP for detecting yellow fever virus in non-human primates samples from Brazil

Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism

Exploring structural antigens of yellow fever virus to design multi-epitope subunit vaccine candidate by utilizing an immuno-informatics approach

Yellow Fever Emergence: Role of Heterologous Flavivirus Immunity in Preventing Urban Transmission

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development

Entomological investigations into yellow fever outbreak in northern Ghana

Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models

Characterization of Enzyme-Linked Immunosorbent Assay (ELISA) for Quantification of Antibodies against Salmonella Typhimurium and Salmonella Enteritidis O-Antigens in Human Sera

Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein

Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever Patients

A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.